Skip to content

Cytokinetics CYTK Other Non-Current Assets

Other Non-Current Assets at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$6.08B+3.7%
Eli Lilly logo
Eli LillyLLY
Merck & Co. logo
Merck & Co.MRK
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
Corcept Therapeutics logo
Corcept TherapeuticsCORT
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$19.4M+1,126%
Operating income-$183.6M-18.0%
Net income-$206.0M-27.7%
EPS (diluted)-$1.67-22.8%

Balance sheet

See full
Cash & equivalents$129.8M+76.2%
Total debt$418.2M+75.8%
Total equity-$826.6M-210%
Total assets$1.3B+0.7%

Cash flow

See full
Operating cash flow-$145.5M-10.5%
CapEx$5.9M+4.7%
Free cash flow-$151.4M-10.3%

Valuation

See full
Market cap$10.7B+70.6%
Enterprise value$10.98B+70.7%
P/S101.1×-225×

Profitability

See full
Operating margin-605.1%-268pp
Net margin-784%-337pp
FCF margin-518.8%-223pp

Returns & leverage

See full
Return on equity-337.6%
Debt / equity2.2×
Current ratio4.2×-1.8×

Where this comes from

Reported directly by Cytokinetics in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cytokinetics's other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cytokinetics's other non-current assets?
Cytokinetics (CYTK) reported other non-current assets of $18.47M in Q1 2026.
How has Cytokinetics's other non-current assets changed year-over-year?
Cytokinetics's other non-current assets increased by 45.5% year-over-year, from $12.7M to $18.47M.
What is the long-term trend for Cytokinetics's other non-current assets?
Over 5 years (2020 to 2025), Cytokinetics's other non-current assets has grown at a 22.2% compound annual growth rate (CAGR), from $6.36M to $17.34M.